Baron SMID Cap ETF sold its position in Insulet Corporation during the second quarter of 2026, according to the fund's quarterly investor letter. The fund said it exited the tubeless automated insulin delivery maker to re-evaluate an accelerating competitive landscape and to assess a series of safety issues affecting Insulet's AID production. Insulet has over 600,000 active global customers and reported $2.7 billion in revenues in 2025, a fraction of the $19 billion worldwide type 1 diabetes market it predicts for 2028, plus an additional $12 billion type 2 market in 2028. The fund said it admires the company and its products and is keeping Insulet on its radar. Insulet closed at $140.60 per share on September 16, 2026, down 4.27% over the past month and 57.84% over the past 52 weeks, with a market capitalization of $9.75 billion and a 52-week range of $126.40 to $354.88.
Insulet CorporationBaron SMID Cap ETF exited Insulet over an accelerating competitive landscape in the tubeless automated insulin delivery market.
